| Field | Specification |
|---|---|
| Target | |
| Alternative names | MRPS18A; 28S ribosomal protein S18a; mitochondrial; MRP-S18-a; Mrps18a; S18mt-a; 28S ribosomal protein S18-3, mitochondrial; MRP-S18-3 |
| Gene ID | |
| UniProt # | |
| Host | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | The antiserum was produced against synthesized peptide derived from human MRPS18A. AA range:81-130 |
| Conjugate | |
| Purification | |
| Concentration | |
| Formulation | |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Scientific Background
Mammalian mitochondrial ribosomal proteins are encoded by nuclear genes and help in protein synthesis within the mitochondrion. Mitochondrial ribosomes (mitoribosomes) consist of a small 28S subunit and a large 39S subunit. They have an estimated 75% protein to rRNA composition compared to prokaryotic ribosomes, where this ratio is reversed. Another difference between mammalian mitoribosomes and prokaryotic ribosomes is that the latter contain a 5S rRNA. Among different species, the proteins comprising the mitoribosome differ greatly in sequence, and sometimes in biochemical properties, which prevents easy recognition by sequence homology. MRPS18A (mitochondrial ribosomal protein S18A) encodes a 28S subunit protein that belongs to the ribosomal protein S18P family. The encoded protein is one of three that has significant sequence similarity to bacterial S18 proteins. The primary sequences of the three human mitochondrial S18 proteins are no more closely related to each other than they are to the prokaryotic S18 proteins. A pseudogene corresponding to MRPS18A is found on chromosome 3p. Alternative splicing results in multiple transcript variants.
Product Overview
This polyclonal antibody, raised in Rabbit, recognizes MRPS18A. It is validated for Immunohistochemistry, ELISA.
Validated Applications
| Applications | Immunohistochemistry, ELISA |
|---|
Optimal dilutions should be determined by the end user for each application and sample type.
Immunogen
The antiserum was produced against synthesized peptide derived from human MRPS18A. AA range:81-130
Specifications
| Host | Rabbit |
|---|---|
| Clonality | Polyclonal |
| Isotype | IgG |
| Conjugate | Unconjugated |
| Reactivity | Human, Mouse, Rat |
| Immunogen | The antiserum was produced against synthesized peptide derived from human MRPS18A. AA range:81-130 |
| Purification | The antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen. |
| Concentration | 1 mg/ml |
| Formulation | Liquid in PBS containing 50% glycerol, 0.5% BSA and 0.02% sodium azide. |
| Target MW | 22184 Da |
| UniProt Accession | Human: Q9NVS2; Mouse: Q99N85 |
| Gene ID | Human: 55168; Mouse: 68565 |
| Storage | -20°C for 1 year |
| Lead Time | Within one week |
Reactivity Notes
Validated reactivity: Human, Mouse, Rat. For other species, epitope conservation may allow cross-reactivity; confirm with appropriate controls.
Safety & Handling
This product is for research use only (RUO) and is not intended for diagnostic or therapeutic use. The formulation contains sodium azide; handle with standard laboratory precautions.
Related Products
Explore related antibodies and reagents for MRPS18A research from Bioassay Technology Laboratory, or contact us for alternative formats.
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
